Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
5 hedge funds and large institutions have $2.58M invested in Blueprint Medicines in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 345 closing their positions.
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
99% less funds holding
Funds holding: 355 → 5 (-350)
100% less capital invested
Capital invested by funds: $8.65B → $2.58M (-$8.65B)
100% less funds holding in top 10
Funds holding in top 10: 30 → 0 (-30)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 345
104.5% less ownership
Funds ownership: 104.54% → 0.04% (-104%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
+$2.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$822M |
| 2 |
BlackRock
New York
|
-$784M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$500M |
| 4 |
HI
HBK Investments
Dallas,
Texas
|
-$410M |
| 5 |
State Street
Boston,
Massachusetts
|
-$286M |
BPMC Hedge Fund Activity: Q3 2025 in Review
5 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2025, worth a combined $2.58M — down 100% from $8.65B a quarter earlier.
Sellers outnumbered buyers: 345 funds closed out of BPMC and 0 opened new positions — a net loss of 345 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was IFP Advisors, adding an estimated $2.06K. The largest seller was Vanguard Group, exiting entirely with an estimated $822M sold.
- 5 institutional investors held Blueprint Medicines (BPMC) as of Q3 2025, down from 355 in Q2 2025.
- Funds reported $2.58M of Blueprint Medicines stock for Q3 2025, down 100% quarter-over-quarter.
- 0 funds opened new Blueprint Medicines positions in Q3 2025 and 345 closed out, a net change of -345 holders.
- The largest Blueprint Medicines buyer in Q3 2025 was IFP Advisors, an estimated $2.06K added.
- The largest Blueprint Medicines seller in Q3 2025 was Vanguard Group, an estimated $822M sold.
Based on aggregated 13F filings for Q3 2025.